ISEV Meeting (International Society of Extracellular Vesicles)

描述（由申请人提供）：外泌体（微囊泡，转录组）是30-150nM的囊泡，含有来自原细胞的蛋白质、mRNA、miRNA和RNA。Exo/MCV可分泌到生物体液（血浆、血清、脊髓液、尿液）中，并可从这些体液中纯化。此R13应用程序支持将在马萨诸塞州总医院（与MGH学院联合）和马萨诸塞州波士顿的公园广场酒店和会议中心举行的ISEV（国际细胞外囊泡学会）第二届国际会议。2013年4月16日至20日。会议将邀请美国临床医生（来自波士顿医学和生物技术界）将ISEV的550名基础科学家的工作转化为临床护理。会议将强调微囊泡（MCV）、外泌体（EXO）、转录组在病毒和细菌抗原呈递、细胞-细胞mRNA相互作用、mcRNA和蛋白质相互作用以及免疫调节剂、凝血成分和肿瘤特异性蛋白质和RNA突变呈递中的临床作用。将举行CME认可的教育日和全体会议，以补充三个平行的口头会议。ISEV 2013会议和支持它的R13将接待750-1000名与会者，并强调定义MCV/EXO颗粒的共识标准，关于制备和分离技术的协议以及规范标本生物库；为支持肿瘤学、传染病和免疫学领域的生物标志物验证研究的联盟建立基础。没有其他会议提供ISEV Boston 2013的范围和参与。NIH主任办公室（Elizabeth Wilder）已经确定了EXO/MCV研究的极大兴趣，并将规范库和RNA研究作为优先事项，将在会议上讨论。会议提供了一个机会，将ISEV的欧洲重点转移到扩大与美国和加拿大研究人员的互动。一个杰出的国际小组和波士顿地区的研究人员将形成96个口头报告和270个主题分组的“虚拟网络海报”的焦点。教育日和全体会议将被录音和网络广播，以供医科学生、相关领域的研究人员以及代表性不足的少数民族和妇女使用。四个旅行奖学金将支持这些少数民族。会议中心符合ADA标准。

DESCRIPTION (provided by applicant): Exosomes (Microvesicles, transcriptomes) are 30-150nM vesicles containing proteins, mRNA, miRNA, and RNA derived from the cell of origin. The Exo/MCV aresecreted into biofluids (plasma, sera, spinal fluid, urine) and can be purified from these fluids. This R13 application supports the Second International Meeting of ISEV (International Society of Extracellular Vesicles) to be held at the Massachusetts General Hospital (in conjunction with The MGH Academy) and the Park Plaza Hotel and Conference Center in Boston, MA. April 16-20, 2013. The meeting will bring American clinicians (from the Boston medical and bio-technology communities) to translate to clinical care the work of the 550 basic scientists of ISEV. The meeting will emphasize the clinical roles of microvesicles (MCV), exosomes (EXO), transcriptomes in presentation of viral and bacterial antigens, interactions of cell-cell mRNA, as well as mcRNA and protein interactions and presentation of immune-regulators, coagulation components and tumor specific protein and RNA mutations. A CME accredited Educational Day and plenary sessions complementing three parallel oral sessions will occur. The ISEV 2013 meeting and the R13 that supports it, will host 750-1000 attendees and emphasize consensus standards by which to define MCV/EXO particles, agreements on preparative and isolation techniques and normative specimen biorepositories; set the basis for consortia that support biomarker validation studies in oncology, infectious diseases, and immunology. There exists no other meeting that offers the scope and participation of ISEV Boston 2013. The NIH Director's office (Elizabeth Wilder) has identified EXO/MCV studies of great interest and made normative repositories and RNA studies a priority which will be addressed at the meeting. The meeting provides an opportunity to shift the European focus of ISEV to broaden interaction with American and Canadian investigators. A distinguished international panel along with Boston area researchers will shape the focus of ninety-six oral presentations and 270 thematically- grouped 'virtual web posters'. The Educational Day and plenary sessions will be recorded and web - broadcast for service to medical students, researchers in allied fields and to serve under- represented minorities and women. Four traveling fellowships will support these minorities. The Conference Center is ADA compliant.